Anavex Life Sciences Corp (AVXL)

[bas2020]

Might it be TauRx? If so, I'm not too concerned.

The Tau protein has already been implicated in the onset of Alzheimer’s, with many biotechs on the hunt for a preventative therapy. Now, a University of Aberdeen (UK) associated biotech, TauRX, have drawn €120M for their phase III therapy. With a major researcher from Cambridge (UK) leading the trials and a dramatic set of phase II results, this latest investment could push the Biotech industry into a whole new era for Alzheimer‘s research.

TauRx-Logo-01TauRX is a spin-off biotech from the University of Aberdeen in Scotland (UK) where its clinical trials are being conducted, although its official headquarters are based in Singapore (for tax reasons, perhaps?!). Their Alzheimer’s pipeline has led to the latest generation of their Tau-aggregation inhibitors (TAIs) attracting a massive €120M funding round for its phase III trials.